Overview

The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery

Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate safety and efficacy of Cerebrolysin as add-on therapy to standard care in patients with acute traumatic brain injury (TBI). The study duration for each patient is 180 days.
Phase:
Phase 4
Details
Lead Sponsor:
Ever Neuro Pharma GmbH
Treatments:
Cerebrolysin